



Ilaris[®] (canakinumab) – Expanded indication

- On June 16, 2020, the [FDA announced](#) the [approval](#) of Novartis' [Ilaris \(canakinumab\)](#), for the treatment of active Still's disease, including Adult-Onset Still's Disease (AOSD) in patients aged 2 years and older.
- Ilaris is also approved for the treatment of active Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 years and older and various autoinflammatory Periodic Fever Syndromes.
- Ilaris is the first FDA approved treatment for AOSD.
- AOSD is a rare and serious autoinflammatory disease of unknown origin. Characteristics of AOSD have considerable overlap with SJIA, which includes fever, arthritis, rash and elevated markers for inflammation. The overlapping features of AOSD and SJIA suggest this is a disease continuum rather than two separate diseases.
- The efficacy of Ilaris in adults with AOSD is based on the pharmacokinetic exposure and extrapolation of the established efficacy of Ilaris in SJIA patients. Efficacy of Ilaris was also assessed in a randomized, double-blind, placebo-controlled study that enrolled 36 patients (22 to 70 years old) diagnosed with AOSD. The efficacy data were generally consistent with the results of a pooled efficacy analysis of SJIA patients.
- The most common adverse reactions (> 10%) with Ilaris use for Still's disease were infections (nasopharyngitis and upper respiratory tract infections), abdominal pain, and injection-site reactions.
- The recommended dose of Ilaris for patients with AOSD with a body weight greater than or equal to 7.5 kg is 4 mg/kg (with a maximum of 300 mg) administered subcutaneously every 4 weeks.
 - Refer to the Ilaris drug label for dosing for all its other indications.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.